Paloma Partners’s Prime Medicine PRME Stock Holding History

Paloma Partners’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,587	Closed	-$44.8K	–	903
2024 Q3	$44.8K	Buy	+11,587	New	+$53.7K	﹤0.01%	1075

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's PRME Position: Q4 2024 in Review

Paloma Partners sold out of Prime Medicine (PRME) in Q4 2024, closing a stake of 11,587 shares — an estimated $44.8K sold.

Paloma Partners first reported a position in PRME in Q3 2024 and held it in 1 quarter. The position peaked at $44.8K in Q3 2024. 131 funds tracked by Wall St. Rank hold PRME as of Q4 2024.

Paloma Partners reported no remaining Prime Medicine position as of Q4 2024 after selling out during the quarter.
Paloma Partners sold 11,587 Prime Medicine shares in Q4 2024, an estimated $44.8K.
Paloma Partners first reported a position in Prime Medicine in Q3 2024 and held it in 1 quarter.
Paloma Partners's Prime Medicine position peaked at $44.8K in Q3 2024.
131 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.